Viewing Study NCT01962103


Ignite Creation Date: 2025-12-24 @ 7:17 PM
Ignite Modification Date: 2026-02-20 @ 1:40 PM
Study NCT ID: NCT01962103
Status: COMPLETED
Last Update Posted: 2019-12-27
First Post: 2013-09-27
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Sponsor: Celgene
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neuroblastoma View
None Rhabdomyosarcoma View
None Ewing's Sarcoma View
None Ewing's Tumor View
None Sarcoma, Ewing's View
None Sarcomas, Epitheliod View
None Sarcoma, Soft Tissue View
None Sarcoma, Spindle Cell View
None Melanoma View
None Malignant Melanoma View
None Clinical Oncology View
None Oncology, Medical View
None Pediatrics, Osteosarcoma View
None Osteogenic Sarcoma View
None Osteosarcoma Tumor View
None Sarcoma, Osteogenic View
None Tumors View
None Cancer View
None Neoplasia View
None Neoplasm View
None Histiocytoma View
None Fibrosarcoma View
None Dermatofibrosarcoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Neuroblastoma View
None Rhabdomyosarcoma View
None Soft Tissue View
None Pediatric Oncology View
None Abraxane View
None albumin-bound paclitaxel View
None nab-paclitaxel View
None ABI-007 View
None taxane View
None solid tumors View